In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
As of close of business last night, Arcutis Biotherapeutics Inc’s stock clocked out at $15.87, down -3.35% from its previous closing price of $16.42. In other words, the price has decreased by -$3.35 from its previous closing price. On the day, 3.44 million shares were traded. ARQT stock price reached its highest trading level at $16.35 during the session, while it also had its lowest trading level at $15.4501.
Ratios:
To gain a deeper understanding of ARQT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.97 and its Current Ratio is at 4.15. In the meantime, Its Debt-to-Equity ratio is 0.70 whereas as Long-Term Debt/Eq ratio is at 0.70.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 30, 2024, initiated with a Buy rating and assigned the stock a target price of $19.
On August 28, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $15.
Mizuho Upgraded its Neutral to Buy on January 03, 2024, whereas the target price for the stock was revised from $4 to $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 13 ’25 when Burnett Patrick sold 49,161 shares for $14.98 per share. The transaction valued at 736,403 led to the insider holds 121,936 shares of the business.
Burnett Patrick sold 12,242 shares of ARQT for $184,107 on Mar 14 ’25. The insider now owns 121,936 shares after completing the transaction at $15.04 per share. On Mar 04 ’25, another insider, Burnett Patrick, who serves as the Officer of the company, bought 12,242 shares for $15.04 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARQT now has a Market Capitalization of 1882785024 and an Enterprise Value of 1765418752. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.58 while its Price-to-Book (P/B) ratio in mrq is 11.87. Its current Enterprise Value per Revenue stands at 8.982 whereas that against EBITDA is -14.034.
Stock Price History:
The Beta on a monthly basis for ARQT is 1.68, which has changed by 0.4694444 over the last 52 weeks, in comparison to a change of 0.07465422 over the same period for the S&P500. Over the past 52 weeks, ARQT has reached a high of $17.70, while it has fallen to a 52-week low of $6.99. The 50-Day Moving Average of the stock is 16.35%, while the 200-Day Moving Average is calculated to be 43.88%.
Shares Statistics:
It appears that ARQT traded 2.31M shares on average per day over the past three months and 2828060 shares per day over the past ten days. A total of 117.85M shares are outstanding, with a floating share count of 104.34M. Insiders hold about 12.05% of the company’s shares, while institutions hold 101.79% stake in the company. Shares short for ARQT as of 1740700800 were 19766505 with a Short Ratio of 8.55, compared to 1738281600 on 18914622. Therefore, it implies a Short% of Shares Outstanding of 19766505 and a Short% of Float of 20.549999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
